Literature DB >> 34363509

Zoledronic Acid Deteriorates Soft and Hard Tissue Healing of Murine Tooth Extraction Sockets in a Dose-Dependent Manner.

Ryohei Kozutsumi1, Shinichiro Kuroshima2, Haruka Kaneko1, Muneteru Sasaki1, Akira Ishisaki3, Takashi Sawase1.   

Abstract

The pathophysiology, histopathology, and immunopathology of bisphosphonate-related osteonecrosis of the jaw (BRONJ) Stage 0 remain unclear. The aim of this study was to investigate the effects of high-dose bisphosphonates on tooth extraction socket healing by creating a murine model of BRONJ Stage 0-like lesions using 8-week-old female C57BL/6J mice. Zoledronic acid (Zol) was administered subcutaneously twice a week for 7 weeks at doses of 0.1 mg/kg/week (moderate dose; Zol-M), 0.5 mg/kg/week (high dose; Zol-H1), and 1.0 mg/kg/week (higher dose; Zol-H2). Saline was used as a control (VC). Both maxillary first molars were extracted 3 weeks after drug treatment. Maxillae, long bones, and sera were collected 4 weeks post-extraction (n = 7 mice/group). Microcomputed tomography, histological, immunohistochemical, and ELISA analyses were performed. A ceiling effect for Zol was noted at the Zol-H1 dose. Osseous healing of extraction sites was significantly impaired with increased necrotic bone and the number of empty lacunae in a Zol dose-dependent manner. Zol significantly decreased epithelial thickness, due to a decrease in thickness of the stratum spinosum, in both Zol-H1 and Zol-H2. Both Zol-H1 and Zol-H2 significantly suppressed the distribution of F4/80+ macrophages in the connective tissue of tooth extraction sockets, although gross healing appeared to be normal. Intriguingly, both Zol-H1 and Zol-H2 significantly increased the numbers of TRAP+ mononuclear cells and detached osteoclasts in the connective tissue and bone marrow of extraction sites compared to VC and Zol-M, correlated with serum TRAcP5b levels. The created murine model of BRONJ Stage 0-like lesions becoming more severe in a dose-dependent manner may help to understand the pathophysiology and histopathology of BRONJ Stage 0 in humans.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Osteonecrosis of the jaw; Stage 0; Tooth extraction; Wound healing; Zoledronic acid

Mesh:

Substances:

Year:  2021        PMID: 34363509     DOI: 10.1007/s00223-021-00890-9

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  55 in total

1.  Osteonecrosis of the jaw in a patient on Denosumab.

Authors:  Tara L Aghaloo; Alan L Felsenfeld; Sotirios Tetradis
Journal:  J Oral Maxillofac Surg       Date:  2010-02-10       Impact factor: 1.895

Review 2.  Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.

Authors:  J Chang; A E Hakam; L K McCauley
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

Review 3.  Osteoporosis: a still increasing prevalence.

Authors:  Jean-Yves Reginster; Nansa Burlet
Journal:  Bone       Date:  2006-02       Impact factor: 4.398

Review 4.  Denosumab and bisphosphonates: different mechanisms of action and effects.

Authors:  Roland Baron; Serge Ferrari; R Graham G Russell
Journal:  Bone       Date:  2010-12-09       Impact factor: 4.398

5.  Osteonecrosis of the jaws induced by anti-RANK ligand therapy.

Authors:  K H Taylor; L S Middlefell; K D Mizen
Journal:  Br J Oral Maxillofac Surg       Date:  2010-04       Impact factor: 1.651

6.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

7.  Hip fractures in the elderly: a world-wide projection.

Authors:  C Cooper; G Campion; L J Melton
Journal:  Osteoporos Int       Date:  1992-11       Impact factor: 4.507

8.  [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].

Authors:  B Svejda; Ch Muschitz; R Gruber; Ch Brandtner; Ch Svejda; R W Gasser; G Santler; H P Dimai
Journal:  Wien Med Wochenschr       Date:  2016-02

Review 9.  Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.

Authors:  Aliya A Khan; Archie Morrison; David A Hanley; Dieter Felsenberg; Laurie K McCauley; Felice O'Ryan; Ian R Reid; Salvatore L Ruggiero; Akira Taguchi; Sotirios Tetradis; Nelson B Watts; Maria Luisa Brandi; Edmund Peters; Teresa Guise; Richard Eastell; Angela M Cheung; Suzanne N Morin; Basel Masri; Cyrus Cooper; Sarah L Morgan; Barbara Obermayer-Pietsch; Bente L Langdahl; Rana Al Dabagh; K Shawn Davison; David L Kendler; George K Sándor; Robert G Josse; Mohit Bhandari; Mohamed El Rabbany; Dominique D Pierroz; Riad Sulimani; Deborah P Saunders; Jacques P Brown; Juliet Compston
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741

10.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

View more
  2 in total

1.  Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues, anti-inflammatory agents or antibiotics.

Authors:  Tomoya Soma; Ryotaro Iwasaki; Yuiko Sato; Tami Kobayashi; Eri Ito; Tatsuaki Matsumoto; Atsushi Kimura; Kana Miyamoto; Morio Matsumoto; Masaya Nakamura; Mayu Morita; Seiji Asoda; Hiromasa Kawana; Taneaki Nakagawa; Takeshi Miyamoto
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

2.  Indigenous microbiota protects development of medication-related osteonecrosis induced by periapical disease in mice.

Authors:  Wen Du; Mengyu Yang; Terresa Kim; Sol Kim; Drake W Williams; Maryam Esmaeili; Christine Hong; Ki-Hyuk Shin; Mo K Kang; No-Hee Park; Reuben H Kim
Journal:  Int J Oral Sci       Date:  2022-03-21       Impact factor: 6.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.